CSL Ltd. shares surged 16.4% on Tuesday after the Australian biotech company upgraded its full-year outlook for fiscal 2026, citing stronger-than-expected demand for its plasma-derived therapies and operational efficiencies.
The company, which specializes in blood plasma products, now expects FY2026 revenue growth of 12-14%, up from its prior guidance of 8-10%. Adjusted net profit is projected to rise 15-17%, compared with the previous forecast of 10-12%. CSL attributed the upgrade to robust demand in its core markets, including North America and Europe, as well as cost savings from its global manufacturing optimization program.
CSL’s chief executive officer, Paul McKenzie, noted that the revised guidance reflects "strong underlying momentum" across the business, particularly in immunoglobulin therapies, which remain a key growth driver. The company also highlighted progress in expanding its plasma collection network, which has supported higher production volumes.
Analysts at UBS and Macquarie raised their price targets on CSL following the announcement, with UBS lifting its target to A$420 from A$380 and Macquarie to A$410 from A$370. The stock closed at A$401.50, up 16.4% from Monday’s close, marking a record intraday high.
CSL’s shares have gained approximately 25% over the past year, outperforming the broader S&P/ASX 200 index, which has risen around 8% in the same period. The company’s market capitalization now exceeds A$180 billion, solidifying its position as one of Australia’s largest listed companies.
Investors will closely monitor CSL’s next earnings report, scheduled for August 2025, for further updates on its operational performance and market dynamics.
